UiPath (NYSE:PATH) Price Target Increased to $27.00 by Analysts at Evercore ISI

UiPath (NYSE:PATH) had its price target hoisted by Evercore ISI from $24.00 to $27.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “in-line” rating on the healthcare company’s stock. Evercore ISI’s price objective would indicate a potential upside of 17.06% from the company’s previous close.

Other analysts also recently issued reports about the stock. William Blair began coverage on shares of UiPath in a research note on Tuesday, January 2nd. They set an “outperform” rating on the stock. Needham & Company LLC upped their price target on shares of UiPath from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. TD Cowen upped their price target on shares of UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. Mizuho increased their target price on shares of UiPath from $18.00 to $22.00 and gave the stock a “neutral” rating in a research report on Friday, December 1st. Finally, Barclays increased their target price on shares of UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Friday. Nine analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $27.13.

UiPath Trading Up 1.4 %

NYSE:PATH traded up $0.32 during trading hours on Thursday, hitting $23.07. 9,842,354 shares of the stock traded hands, compared to its average volume of 10,074,664. The firm has a 50 day moving average price of $23.52 and a 200 day moving average price of $20.70. UiPath has a fifty-two week low of $12.38 and a fifty-two week high of $27.87. The firm has a market cap of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97.

Insider Transactions at UiPath

In other news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the transaction, the director now directly owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now directly owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the sale, the chief financial officer now directly owns 103,505 shares in the company, valued at $2,325,757.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 411,000 shares of company stock worth $9,418,670. Company insiders own 31.03% of the company’s stock.

Institutional Investors Weigh In On UiPath

A number of institutional investors have recently added to or reduced their stakes in PATH. Mark Sheptoff Financial Planning LLC acquired a new stake in UiPath during the fourth quarter valued at approximately $25,000. HighMark Wealth Management LLC bought a new position in shares of UiPath in the fourth quarter valued at approximately $27,000. Tyler Stone Wealth Management bought a new position in shares of UiPath in the second quarter valued at approximately $28,000. Cypress Capital Management LLC WY bought a new position in shares of UiPath in the fourth quarter valued at approximately $29,000. Finally, Fifth Third Bancorp raised its stake in shares of UiPath by 2,005.3% in the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock valued at $34,000 after acquiring an additional 1,905 shares during the last quarter. 59.04% of the stock is owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.